MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dopamine"

  • 2026 International Congress

    A Dopamine Clock for Biological Staging of Parkinson’s Disease

    R. Gunn, G. Searle, G. Rizzo, Z. Fan, T. Tropea, T. Simuni, K. Poston, A. Siderowf, L. Chahine, J. Seibyl, K. Marek (London, United Kingdom)

    Objective: To develop a dopamine transporter (DAT) SPECT imaging staging framework for Parkinson’s disease (PD) using a latent disease-time model that quantifies progression as a…
  • 2026 International Congress

    A case of monotherapy with intracerebroventricular anaerobic dopamine allows complete control of Parkinson’s disease symptoms

    C. Moreau, F. Marchand, J. Bene, C. Leclercq, V. Foutel, M. Fisichella, D. Devos (Lille, France)

    Objective: To investigate the safety and efficacy of continuous circadian and personalized intracerebroventricular (i.c.v.) administration of anaerobic dopamine (A-dopamine) in Parkinson's disease patients refractory to…
  • 2026 International Congress

    A novel pro-drug overcomes short-half life and absorption challenges and increase brain penetration of dopamine as a potential therapy for Parkinson’s disease

    C. Moussa (Washington DC, USA)

    Objective: We developed a new small molecule drug candidate that would increase the effectiveness of dopamine delivery to the brain. We also sought to mitigate…
  • 2025 International Congress

    Evaluation of Neuroprotective Effect of Terminalia macroptera on Rotenone Induced Parkinson’s Disease in Mice

    L. Ior, E. Ishaya, P. Ezeuduji (Jos, Nigeria)

    Objective: This study investigates the neuroprotective effects of an aqueous extract of Terminalia macroptera (AETM) in a rotenone-induced Parkinsonism mouse model. Background: Parkinson’s disease (PD)…
  • 2025 International Congress

    The neuroprotective effects of Echinacoside on α-synuclein fibril-induced Parkinson’s disease mice model

    Q. Zhao, S. Bu, Z. Wang, L. Jin (Shanghai, China)

    Objective: This study further investigates the ameliorative effects of ECH on neurobehavioral abnormalities and nigrostriatal dopaminergic system impairment in α-synuclein preformed fibrils (α-Syn PFFs)-induced PD…
  • 2025 International Congress

    Chronic DBS Stimulation’s effects after 1-hour off stimulation

    M. Varga, Y. Zhao, S. Santacruz (Austin, USA)

    Objective: This study investigates the changes in local field potential (LFP) activity during chronic deep brain stimulation (DBS) in patients with Parkinson's disease (PD) during…
  • 2025 International Congress

    Cognitive and Neuropsychiatric Dysfunction is Associated with Corticostriatal Synucleinopathy in the Alpha-Synuclein Preformed Fibril Rat Model of Parkinson’s Disease

    J. Bechtold, J. Patterson, C. Kemp, A. Stoll, S. Arrington, M. Venard, L. Mayle, V. Field, J. Holden, C. Sortwell, S. Fleming (Rootstown, USA)

    Objective: To investigate the role of corticostriatal synucleinopathy on behavioral function in an alpha-synuclein preformed fibril (a-Syn PFF) rat model of Parkinson’s disease (PD). Background:…
  • 2025 International Congress

    The efficacy and safety of continuous subcutaneous infusion therapy with foslevodopa/foscarbidopa

    M. Shiraishi, N. Takao, Y. Nakano, Y. Yamano (Kawasaki City, Japan)

    Objective: To clarify the actual status of CSCI therapy, cases in which CSCI therapy was started at our hospital were investigated. Background: Continuous subcutaneous infusion…
  • 2025 International Congress

    A Biomarker-Directed Approach to the Early Diagnosis of Parkinson’s Disease Using Artificial Intelligence and Machine Learning

    ME. Mellaci (SÃO PAULO, Brazil)

    Objective: The main purpose of this study was to assess how AI and ML methods integrate multiple biomarkers for diagnosing Parkinson’s Disease (PD) to improve…
  • 2025 International Congress

    Metabolomic Profiling in an Egyptian Cohort Reveals Altered Phenylalanine Metabolism and Suggests a Role for Trans-Cinnamate in Parkinson Disease

    N. Shebl, S. El-Jafaary, A. Saeed, P. Elkafrawy, A. El-Sayed, S. Shamma, R. Elmer, J. Mekky, L. Mohamed, O. Kittaneh, H. El-Fawal, M. Rizig, M. Salama (Cairo, Egypt)

    Objective: Investigate the associated metabolic changes in PD via a comprehensive metabolic analysis with a focus on phenylalanine (dopamine precursor) metabolism and its impact on…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 27
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley